{"protocolSection":{"identificationModule":{"nctId":"NCT03158038","orgStudyIdInfo":{"id":"D2560C00014"},"organization":{"fullName":"MedImmune LLC","class":"INDUSTRY"},"briefTitle":"Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season","officialTitle":"A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults","acronym":"FluMist"},"statusModule":{"statusVerifiedDate":"2018-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-05-30","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2017-12-14","type":"ACTUAL"},"completionDateStruct":{"date":"2017-12-14","type":"ACTUAL"},"studyFirstSubmitDate":"2017-05-16","studyFirstSubmitQcDate":"2017-05-16","studyFirstPostDateStruct":{"date":"2017-05-17","type":"ACTUAL"},"resultsFirstSubmitDate":"2018-12-10","resultsFirstSubmitQcDate":"2018-12-10","resultsFirstPostDateStruct":{"date":"2019-01-04","type":"ACTUAL"},"lastUpdateSubmitDate":"2018-12-10","lastUpdatePostDateStruct":{"date":"2019-01-04","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"MedImmune LLC","class":"INDUSTRY"},"collaborators":[{"name":"AstraZeneca","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This prospective annual release study is designed to evaluate the safety of 1 new influenza virus vaccine strain to be included in FluMist Quadrivalent for the 2017-2018 influenza season.","detailedDescription":"This prospective, randomized, double-blind, placebo-controlled release study will enroll approximately 300 healthy adults 18 to 49 years of age (not yet reached their 50th birthday). Eligible participants will be randomly assigned in a 4:1 fashion to receive a single dose of monovalent vaccine or placebo by intranasal spray. Randomization will be stratified by site. This study will be conducted at 2 sites in the United States of America. Each participant will receive 1 dose of investigational product on Day 1. The duration of study participation for each participant is the time from study vaccination through 180 days after study vaccination."},"conditionsModule":{"conditions":["Influenza","Healthy"],"keywords":["Trivalent","Influenza","FluMist Quadrivalent","Vaccine","Prevention","Healthy","Monovalent"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","maskingDescription":"Double-blind","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":300,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Monovalent Influenza Vaccine","type":"EXPERIMENTAL","description":"Participants will receive a single dose of monovalent influenza vaccine \\[10\\^7.0 +/- 0.5 fluorescent focus unit (FFU) of each of 1 cold adapted (ca), attenuated (att), temperature sensitive (ts) 6:2 reassortant influenza strain\\] by intranasal spray on Day 1.","interventionNames":["Biological: Monovalent Influenza Vaccine"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Participants will receive a single dose of placebo matching with monovalent influenza vaccine by intranasal spray on Day 1.","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Monovalent Influenza Vaccine","description":"A single dose of monovalent influenza vaccine \\[10\\^7.0 +/- 0.5 FFU of each of 1 ca, att, ts 6:2 reassortant influenza strain\\] will be administered as intranasal spray on Day 1.","armGroupLabels":["Monovalent Influenza Vaccine"]},{"type":"OTHER","name":"Placebo","description":"A single dose of placebo matching with monovalent influenza vaccine will be administered as intranasal spray on Day 1.","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With Fever Greater Than or Equal to (>=) 101 Degrees Fahrenheit (F)","description":"Percentage of participants with fever defined as oral temperature \\>=101 degrees F were reported.","timeFrame":"Baseline (Day 1) up to Day 8"}],"secondaryOutcomes":[{"measure":"Percentage of Participants With Solicited Symptoms","description":"Solicited symptoms are predefined symptoms or events specifically inquired about and assessed daily after vaccine administration up to 15 days after vaccination. The solicited symptoms include fever greater than (\\>) 100.0 degrees F (37.8 degrees Celsius), runny nose, sore throat, cough, vomiting, muscle aches, chills, decreased activity and headache. Results were reported for all solicited symptoms except fever \\>=101 degrees F (reported as primary outcome) up to 8 days after vaccination and all solicited symptoms up to 15 days after vaccination.","timeFrame":"Baseline (Day 1) up to Day 8 and Day 15"},{"measure":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","description":"An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent AEs were events between administration of study drug and up to 15 days after vaccination that are absent before treatment or that worsened relative to pre-treatment state. Results were given for AEs reported up to 8 days and 15 days after vaccination.","timeFrame":"Baseline (Day 1) up to Day 8 and Day 15"},{"measure":"Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) and New Onset Chronic Diseases (NOCDs)","description":"An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent SAEs were serious events between administration of study drug and up to 181 days after the dose that are absent before treatment or that worsen relative to pretreatment state. An NOCD is a newly diagnosed medical condition that is of a chronic, ongoing nature and is assessed by the investigator as medically significant. Results were given for TESAEs and NOCDs reported up to 29 days and 181 days after vaccination.","timeFrame":"Baseline (Day 1) up to Day 29 and Day 181"},{"measure":"Percentage of Participants Who Require Antipyretic and/or Analgesic Medication","description":"Percentage of participants who require antipyretic and/or analgesic medication were reported.","timeFrame":"Baseline (Day 1) up to Day 8 and Day 15"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Age 18 through 49 years\n* Written informed consent\n* Participant available by telephone\n* Ability to understand and comply with the requirements of the protocol, as judged by the Investigator\n\nKey Exclusion Criteria:\n\n* Concurrent enrollment in another clinical study up to 180 days after receipt of investigational product (Day 181)\n* History of hypersensitivity to any component of the vaccine, including egg or egg protein or serious, life threatening, or severe reactions to previous influenza vaccinations\n* Any condition for which the inactivated influenza vaccine is indicated, including chronic disorders of the pulmonary or cardiovascular systems (example \\[eg\\], asthma), chronic metabolic diseases (eg, diabetes mellitus), renal dysfunction, or hemoglobinopathies that required regular medical follow-up or hospitalization during the preceding year\n* Acute febrile (greater than \\[\\>\\] 100.0 degrees Fahrenheit \\[F\\] oral or equivalent) and/or clinically significant respiratory illness (example, cough or sore throat) within 14 days to randomization\n* Any known immunosuppressive condition or immune deficiency diseases, including human immunodeficiency virus infection, or ongoing immunosuppressive therapy\n* History of Guillain-Barre syndrome\n* Receipt of any investigational agent within 30 days prior to randomization, or expected receipt through 30 days after the dose of investigational product (use of licensed agents for indications not listed in the Package Insert is permitted)\n* Receipt of any non-study vaccine within 30 days prior to randomization, or expected receipt through 30 days after receipt of investigational product\n* Expected receipt of antipyretic or analgesic medication on a daily or every other day basis from randomization through 14 days after receipt of investigational product\n* Administration of intranasal medications within 14 days prior to randomization, or expected receipt through 14 days after administration of investigational product\n* Receipt of influenza antiviral therapy or influenza antiviral agents within 48 hours prior to investigational product administration or expected receipt of influenza antiviral therapy or influenza antiviral agents through 14 days after receipt of investigational product","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"49 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Research Site","city":"Stockbridge","state":"Georgia","zip":"30281","country":"United States","geoPoint":{"lat":33.54428,"lon":-84.23381}},{"facility":"Research Site","city":"Portland","state":"Oregon","zip":"97239","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 300 participants were randomized and participated in the study.","recruitmentDetails":"The study was conducted from 30 May 2017 to 14 Dec 2017 at 2 sites in the United States of America (USA).","groups":[{"id":"FG000","title":"Monovalent Influenza Vaccine","description":"Participants received a single dose of monovalent influenza vaccine \\[10\\^7.0 +/- 0.5 fluorescent focus unit (FFU) of each of 1 cold adapted (ca), attenuated (att), temperature sensitive (ts) 6:2 reassortant influenza strain\\] by intranasal spray on Day 1."},{"id":"FG001","title":"Placebo","description":"Participants received a single dose of placebo matching with monovalent influenza vaccine by intranasal spray on Day 1."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"240"},{"groupId":"FG001","numSubjects":"60"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"240"},{"groupId":"FG001","numSubjects":"60"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"The intent-to-treat (ITT) population included all participants who were randomized and treated with investigational product.","groups":[{"id":"BG000","title":"Monovalent Influenza Vaccine","description":"Participants received a single dose of monovalent influenza vaccine \\[10\\^7.0 +/- 0.5 fluorescent focus unit (FFU) of each of 1 cold adapted (ca), attenuated (att), temperature sensitive (ts) 6:2 reassortant influenza strain\\] by intranasal spray on Day 1."},{"id":"BG001","title":"Placebo","description":"Participants received a single dose of placebo matching with monovalent influenza vaccine by intranasal spray on Day 1."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"240"},{"groupId":"BG001","value":"60"},{"groupId":"BG002","value":"300"}]}],"measures":[{"title":"Age, Continuous","populationDescription":"The ITT population included all participants who were randomized and treated with investigational product.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"29.9","spread":"9.5"},{"groupId":"BG001","value":"32.5","spread":"10.5"},{"groupId":"BG002","value":"30.4","spread":"9.8"}]}]}]},{"title":"Sex: Female, Male","populationDescription":"The ITT population included all participants who were randomized and treated with investigational product.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"138"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"171"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"102"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"129"}]}]}]},{"title":"Ethnicity (NIH/OMB)","populationDescription":"The ITT population included all participants who were randomized and treated with investigational product.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"16"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"227"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"284"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","populationDescription":"The ITT population included all participants who were randomized and treated with investigational product.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"42"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"191"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"243"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"9"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Fever Greater Than or Equal to (>=) 101 Degrees Fahrenheit (F)","description":"Percentage of participants with fever defined as oral temperature \\>=101 degrees F were reported.","populationDescription":"The intent-to-treat (ITT) population included all participants who were randomized and treated with investigational product.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Baseline (Day 1) up to Day 8","groups":[{"id":"OG000","title":"Monovalent Influenza Vaccine","description":"Participants received a single dose of monovalent influenza vaccine \\[10\\^7.0 +/- 0.5 fluorescent focus unit (FFU) of each of 1 cold adapted (ca), attenuated (att), temperature sensitive (ts) 6:2 reassortant influenza strains\\] by intranasal spray on Day 1."},{"id":"OG001","title":"Placebo","description":"Participants received a single dose of placebo matching with monovalent influenza vaccine by intranasal spray on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"240"},{"groupId":"OG001","value":"60"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Rate difference","paramValue":"0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-6.7","ciUpperLimit":"1.9"}]},{"type":"SECONDARY","title":"Percentage of Participants With Solicited Symptoms","description":"Solicited symptoms are predefined symptoms or events specifically inquired about and assessed daily after vaccine administration up to 15 days after vaccination. The solicited symptoms include fever greater than (\\>) 100.0 degrees F (37.8 degrees Celsius), runny nose, sore throat, cough, vomiting, muscle aches, chills, decreased activity and headache. Results were reported for all solicited symptoms except fever \\>=101 degrees F (reported as primary outcome) up to 8 days after vaccination and all solicited symptoms up to 15 days after vaccination.","populationDescription":"The ITT population included all participants who were randomized and treated with investigational product.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Baseline (Day 1) up to Day 8 and Day 15","groups":[{"id":"OG000","title":"Monovalent Influenza Vaccine","description":"Participants received a single dose of monovalent influenza vaccine \\[10\\^7.0 +/- 0.5 fluorescent focus unit (FFU) of each of 1 cold adapted (ca), attenuated (att), temperature sensitive (ts) 6:2 reassortant influenza strains\\] by intranasal spray on Day 1."},{"id":"OG001","title":"Placebo","description":"Participants received a single dose of placebo matching with monovalent influenza vaccine by intranasal spray on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"240"},{"groupId":"OG001","value":"60"}]}],"classes":[{"title":"Up to Day 8","categories":[{"measurements":[{"groupId":"OG000","value":"27.9"},{"groupId":"OG001","value":"26.7"}]}]},{"title":"Up to Day 15","categories":[{"measurements":[{"groupId":"OG000","value":"32.1"},{"groupId":"OG001","value":"31.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Statistical analysis up to Day 8","nonInferiorityType":"SUPERIORITY","paramType":"Rate difference","paramValue":"1.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-12.8","ciUpperLimit":"13.2"},{"groupIds":["OG000","OG001"],"groupDescription":"Statistical analysis up to Day 15","nonInferiorityType":"SUPERIORITY","paramType":"Rate difference","paramValue":"0.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-14.1","ciUpperLimit":"13.2"}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","description":"An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent AEs were events between administration of study drug and up to 15 days after vaccination that are absent before treatment or that worsened relative to pre-treatment state. Results were given for AEs reported up to 8 days and 15 days after vaccination.","populationDescription":"The ITT population included all participants who were randomized and treated with investigational product.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Baseline (Day 1) up to Day 8 and Day 15","groups":[{"id":"OG000","title":"Monovalent Influenza Vaccine","description":"Participants received a single dose of monovalent influenza vaccine \\[10\\^7.0 +/- 0.5 fluorescent focus unit (FFU) of each of 1 cold adapted (ca), attenuated (att), temperature sensitive (ts) 6:2 reassortant influenza strains\\] by intranasal spray on Day 1."},{"id":"OG001","title":"Placebo","description":"Participants received a single dose of placebo matching with monovalent influenza vaccine by intranasal spray on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"240"},{"groupId":"OG001","value":"60"}]}],"classes":[{"title":"Up to Day 8","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"0"}]}]},{"title":"Up to Day 15","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) and New Onset Chronic Diseases (NOCDs)","description":"An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent SAEs were serious events between administration of study drug and up to 181 days after the dose that are absent before treatment or that worsen relative to pretreatment state. An NOCD is a newly diagnosed medical condition that is of a chronic, ongoing nature and is assessed by the investigator as medically significant. Results were given for TESAEs and NOCDs reported up to 29 days and 181 days after vaccination.","populationDescription":"The ITT population included all participants who were randomized and treated with investigational product.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Baseline (Day 1) up to Day 29 and Day 181","groups":[{"id":"OG000","title":"Monovalent Influenza Vaccine","description":"Participants received a single dose of monovalent influenza vaccine \\[10\\^7.0 +/- 0.5 fluorescent focus unit (FFU) of each of 1 cold adapted (ca), attenuated (att), temperature sensitive (ts) 6:2 reassortant influenza strains\\] by intranasal spray on Day 1."},{"id":"OG001","title":"Placebo","description":"Participants received a single dose of placebo matching with monovalent influenza vaccine by intranasal spray on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"240"},{"groupId":"OG001","value":"60"}]}],"classes":[{"title":"TESAEs: Up to Day 29","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"NOCDs: Up to Day 29","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"TESAEs: Up to Day 181","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"NOCDs: Up to Day 181","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Require Antipyretic and/or Analgesic Medication","description":"Percentage of participants who require antipyretic and/or analgesic medication were reported.","populationDescription":"The ITT population included all participants who were randomized and treated with investigational product.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Baseline (Day 1) up to Day 8 and Day 15","groups":[{"id":"OG000","title":"Monovalent Influenza Vaccine","description":"Participants received a single dose of monovalent influenza vaccine \\[10\\^7.0 +/- 0.5 fluorescent focus unit (FFU) of each of 1 cold adapted (ca), attenuated (att), temperature sensitive (ts) 6:2 reassortant influenza strains\\] by intranasal spray on Day 1."},{"id":"OG001","title":"Placebo","description":"Participants received a single dose of placebo matching with monovalent influenza vaccine by intranasal spray on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"240"},{"groupId":"OG001","value":"60"}]}],"classes":[{"title":"Up to Day 8","categories":[{"measurements":[{"groupId":"OG000","value":"2.1"},{"groupId":"OG001","value":"1.7"}]}]},{"title":"Up to Day 15","categories":[{"measurements":[{"groupId":"OG000","value":"3.3"},{"groupId":"OG001","value":"6.7"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Adverse Events: Baseline (Day 1) up to Day 15, and Serious Adverse Events: Baseline (Day 1) up to Day 181","eventGroups":[{"id":"EG000","title":"Monovalent Influenza Vaccine","description":"Participants received a single dose of monovalent influenza vaccine \\[10\\^7.0 +/- 0.5 fluorescent focus unit (FFU) of each of 1 cold adapted (ca), attenuated (att), temperature sensitive (ts) 6:2 reassortant influenza strain\\] by intranasal spray on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":240,"seriousNumAffected":1,"seriousNumAtRisk":240,"otherNumAffected":19,"otherNumAtRisk":240},{"id":"EG001","title":"Placebo","description":"Participants received a single dose of placebo matching with monovalent influenza vaccine by intranasal spray on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":60,"seriousNumAffected":0,"seriousNumAtRisk":60,"otherNumAffected":1,"otherNumAtRisk":60}],"seriousEvents":[{"term":"Endometriosis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":240},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]}],"otherEvents":[{"term":"Ear congestion","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":240},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Ear pain","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":240},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":240},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":240},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":240},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Ear infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":240},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Laryngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":240},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":240},{"groupId":"EG001","numAffected":1,"numAtRisk":60}]},{"term":"Musculoskeletal stiffness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":240},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Pain in jaw","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":240},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":240},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Dysmenorrhoea","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":240},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":240},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":240},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Nasal discomfort","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":240},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":240},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Sinus pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":240},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Sneezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":240},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":240},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"MedImmune has 60 days to review results communications prior to public release and may delete information that compromises on-going studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome."},"pointOfContact":{"title":"Raburn Mallory","organization":"MedImmune, LLC","email":"information.center@astrazeneca.com","phone":"+1-301-398-5799"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2017-03-03","uploadDate":"2018-12-10T11:55","filename":"Prot_SAP_000.pdf","size":16172991}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D007251","term":"Influenza, Human"}],"ancestors":[{"id":"D012141","term":"Respiratory Tract Infections"},{"id":"D007239","term":"Infections"},{"id":"D009976","term":"Orthomyxoviridae Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D007252","term":"Influenza Vaccines"}],"ancestors":[{"id":"D014765","term":"Viral Vaccines"},{"id":"D014612","term":"Vaccines"},{"id":"D001688","term":"Biological Products"},{"id":"D045424","term":"Complex Mixtures"}]}},"hasResults":true}